Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: Results from an inter-cohort analysis

Antiviral Therapy

Volumn 11, Issue 5, 2006, Pages 567-574

  Puoti, Massimo ^a   Cozzi Lepri, Alessandro ^b   Arici, Claudio ^c   Moller, Nina Friis ^d   Lundgren, Jens D ^d   Ledergerber, Bruno ^e   Rickenbach, Martin ^e   Suarez Lozano, Ignacio ^f   Garrido, Myriam ^f   Dabis, Francois ^g   Winnock, Maria ^g   Milazzo, Laura ^h   Gervais, Anne ⁱ   Raffi, Francois ⁱ   Gill, John ^j   Rockstroh, Juergen ^k   Qurishi, Nazifa ^k   Mussini, Cristina ^l   Castagna, Antonella ^m   De Luca, Andrea ⁿ   Monforte, Antonella D'Arminio ^m   more..

^a UNIVERSITY OF BRESCIA   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c OSPEDALI RIUNITI   (Italy)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f HOSPITAL INFANTA ELENA   (Spain)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j Southern Alberta Clinic   (Canada)

^k UNIVERSITY OF BONN   (Germany)

^l UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^m Clinica Malattie Infettive e Tropicali   (Italy)

ⁿ CATHOLIC UNIVERSITY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; DIDANOSINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VIRUS TRANSMISSION;

EID: 33747808649     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in human immunodeficiency virus infected subjects. AIDS Rev 2002; 4:28-36.
2. Nuñez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the HIV-infected patients: present and future. Clin Infect Dis 2003; 37:1678-1685.
3. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19:221-240.
4. Bodsworth N, Donovan B, Nightingale BN. The effects of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989; 160:577-825.
5. Gilson R, Hawkins AE, Beecham MR, et al. Interaction between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11:597-606.
6. Colin JF, Cazals-Hatem D, Loriot AM, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310.
7. Di Martino V, Thevenot T, Colin J. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812-1822.
8. Thio CL, Seaberg EC, Skolaski R, et al. HIV-1, hepatitis B virus and risk of liver-related mortality in the Multicenter Cohort Study (MACS) Lancet 2002; 360:1921-1926.
9. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17:1803-1809.
10. Dore JG, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus hepatitis B co-infected persons in a randomised, controlled study (CAESAR). J Infect Dis 1999; 180:607-613
11. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17:F7-F10.
12. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207-210.
13. Liaw YF, Sung JJ, Chow WC, et al. Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
14. Puoti M, Cozzi-Lepri A, Ancarani F, et al. The management of hepatitis B virus/HIV-1 co-infected patients starting their first CART regimen. Treating two infections for the price of one drug? Antivir Ther 2004; 9:811-817.
15. Brook MG, Gilson R, Wilkins E on behalf of the British HIV Association. BHIVA Guidelines: co-infection with HIV and chronic hepatitis B. HIV Med 2003; 4:42-51.
16. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adoscents. 7 April 2005. http://AIDSinfo.nih.gov
17. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European consensus conference on treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:515-624.
18. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1303-1306.
19. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
20. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003; 17:1649-1657.
21. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
22. Fang CT, Chen PJ, Chen MY, et al. Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. J Hepatol 2003; 39:1028-1035.
23. Benhamou Y. Antiretroviral therapy and HIV/hepatitis B virus co-infection. Clin Inf Dis 2004; 38(Suppl 2):S98-S103.
24. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Scmidt RE. Hepatitis B and C in HIV infected patients. Prevalence and prognostic value. J Hepatol 1997; 27:18-24.
25. Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol 2006; 44:S25-S27.
26. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44:S65-S70.
27. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16:2352-2354.
28. Sterne JA, Hernan MA, Ledergerber B, et al.; Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384.
29. Brumback BA, Hernan MA, Haneuse SJ, Robins JM. Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures. Stat Med 2004; 23:749-767.
30. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211-217.
31. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EUROSIDA cohort. AIDS 2005; 19:593-601.
32. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18:2039-2046.
33. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36:s226-s236
34. Bisson G, Gross R, Miller V, et al.; Writing group. Monitoring of long-term toxicities of HIV treatments: an international perspective. AIDS 2003; 17:2407-2417.